- Home
- GNFT vs NBTX Comparison
GNFT vs NBTX Comparison
Compare GNFT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- NBTX
- Stock Information
- Founded
- GNFT 1999
- NBTX 2003
- Country
- GNFT France
- NBTX France
- Employees
- GNFT N/A
- NBTX N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- NBTX Health Care
- Exchange
- GNFT Nasdaq
- NBTX Nasdaq
- Market Cap
- GNFT 189.6M
- NBTX 201.9M
- IPO Year
- GNFT 2019
- NBTX 2020
- Fundamental
- Price
- GNFT $3.80
- NBTX $3.26
- Analyst Decision
- GNFT Strong Buy
- NBTX Strong Buy
- Analyst Count
- GNFT 1
- NBTX 1
- Target Price
- GNFT $13.00
- NBTX $12.00
- AVG Volume (30 Days)
- GNFT 9.8K
- NBTX 64.6K
- Earning Date
- GNFT 09-19-2024
- NBTX 12-31-2024
- Dividend Yield
- GNFT N/A
- NBTX N/A
- EPS Growth
- GNFT N/A
- NBTX N/A
- EPS
- GNFT 0.47
- NBTX N/A
- Revenue
- GNFT $86,225,222.00
- NBTX $45,220,186.00
- Revenue This Year
- GNFT $155.44
- NBTX N/A
- Revenue Next Year
- GNFT N/A
- NBTX N/A
- P/E Ratio
- GNFT $7.53
- NBTX N/A
- Revenue Growth
- GNFT 175.45
- NBTX 526.17
- 52 Week Low
- GNFT $3.31
- NBTX $2.76
- 52 Week High
- GNFT $6.42
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- GNFT 29.24
- NBTX 42.55
- Support Level
- GNFT $3.63
- NBTX $3.18
- Resistance Level
- GNFT $3.88
- NBTX $3.69
- Average True Range (ATR)
- GNFT 0.10
- NBTX 0.27
- MACD
- GNFT 0.02
- NBTX 0.07
- Stochastic Oscillator
- GNFT 15.30
- NBTX 56.45
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.